KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EBITDA for 18 consecutive years, with $661.6 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA fell 21.77% year-over-year to $661.6 million; the TTM value through Mar 2026 reached $4.4 billion, down 4.33%, while the annual FY2025 figure was $4.6 billion, 2.33% up from the prior year.
  • EBITDA hit $661.6 million in Q1 2026 for Regeneron Pharmaceuticals, down from $853.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.5 billion in Q3 2025 and bottomed at $661.6 million in Q1 2026.
  • Average EBITDA over 5 years is $1.1 billion, with a median of $952.3 million recorded in 2023.
  • Year-over-year, EBITDA crashed 74.23% in 2022 and then soared 51.17% in 2024.
  • Regeneron Pharmaceuticals' EBITDA stood at $1.2 billion in 2022, then rose by 1.79% to $1.3 billion in 2023, then crashed by 32.33% to $849.6 million in 2024, then rose by 0.41% to $853.1 million in 2025, then dropped by 22.45% to $661.6 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at $661.6 million, $853.1 million, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.